Alias
科研级 Simtuzumab ( 辛妥珠单抗 ), Anti-LOXL2 Recombinant Antibody, Research Grade Simtuzumab
Molecular Name
Simtuzumab
Applications
FC, IP, ELISA, Neut, FuncS
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
LOXL2[Homo sapiens]
Sequence
Please contact our sales representative to learn more information about this reagents.
Background
Simtuzumab (INN, formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.
Storage
该产品可在 2°C-8°C 下保存一个月,活性不会明显降低。在 -20°C 至 -80°C 下保存,可稳定保存十二个月。避免反复冻融,用冰袋运输。